Milvexian did not reduce ischemic risk in trial of patients with recent ACS

MUNICH — Milvexian did not lower risk for ischemic events compared with placebo in patients who experienced a recent ACS, but also did not increase bleeding risk, a speaker reported.The LIBREXIA trial evaluating the small-molecule factor XIa inhibitor milvexian (Bristol Myers Squibb/Johnson & Johnson) in patients at risk for recurrent ischemic events after an ACS event was halted early